StartUPDATES: New developments from healthcare startups
Check out new developments from Carrum Health, Sema4, Trulla, SpendMend, Monod Bio, and Evry Health.
ViVE conference highlights commitment to health equity, previews the next chapter of interoperability
The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sema4 secures a deal to acquire GeneDx, capturing $200M in private investment
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
Sema4 goes public via SPAC merger
With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
StartUPDATES: New developments from healthcare startups
Read news from healthcare and life science companies including HealthMine, Zus Health, Sema4 and more.
AdventHealth, Sema4 partner to launch precision medicine program
The collaboration will build on AdventHealth's existing genomics and personalized health program, leveraging data to predict disease progression and response to treatments. Sema4's Centrellis data platform will be a core part of the new program.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
StartUPDATES: New developments from healthcare startups
Read about new developments from Blue Therapeutics, Docbot, Sema4, and Deep Lens.
NorthShore, Sema4 set up genomics program to advance personalized treatment
The Illinois-based health system is teaming up with the analytics company to launch a genomics program, which will focus on predicting the risk of illness and outcomes among patients. It will also provide free genetic testing to low-income patients in an effort to increase access to genomic care.
Sema4, a Mount Sinai spinout, launches with a focus on genomics
Mount Sinai Health System's new spinout company, Sema4, will rely on genomic and clinical data to better diagnose, treat and prevent diseases.